FDANonrulemakingFDA-2011-D-0605
Who commented on this docket
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
2 organizations filed 2 public comments on Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, at the Food and Drug Administration. The comment window closed 189d ago.
Organizations
2
Comments
2
RIN
—
Comment window
closed 189d ago
Commenters (2)
- Association for Accessible Medicinestrade assoc.1 filing · confidence 97%
- Parenteral Drug Associationtrade assoc.1 filing · confidence 97%
Attribution is name-based and imperfect. regulations.gov data is public record.